SG
PCSA icon

StoneX Group’s Processa Pharmaceuticals PCSA Stock Holding History

StoneX Group’s Portfolio PCSA Stock Details PCSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$29.6K Buy
+11,437
New +$29.6K ﹤0.01% 1273
2025
Q4 		– Sell
-758
Closed -$3.64K – 1169
2025
Q3 		$3.64K Buy
+758
New +$4K ﹤0.01% 916

Other funds holding PCSA

CCM
Connective Capital Management Palo Alto, California $142M AUM 51.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return

StoneX Group's PCSA Position: Q2 2026 in Review

StoneX Group opened a new position in Processa Pharmaceuticals (PCSA) in Q2 2026: 11,437 shares worth $29.6K. The stake represents ﹤0.01% of the portfolio and ranks #1273 among its holdings. This is a return to the name: StoneX Group previously reported a position in PCSA as recently as Q3 2025.

StoneX Group first reported a position in PCSA in Q3 2025 and has held it in 2 quarters since. 11 funds tracked by Wall St. Rank hold PCSA as of Q2 2026.

  • StoneX Group held 11,437 shares of Processa Pharmaceuticals worth $29.6K as of Q2 2026.
  • Processa Pharmaceuticals was a new StoneX Group position in Q2 2026.
  • Processa Pharmaceuticals made up ﹤0.01% of StoneX Group's portfolio in Q2 2026, its #1273 holding.
  • StoneX Group first reported a position in Processa Pharmaceuticals in Q3 2025 and has held it in 2 quarters since.
  • 11 funds tracked by Wall St. Rank held Processa Pharmaceuticals as of Q2 2026.

Based on StoneX Group's 13F filing for Q2 2026, filed 12 Aug 2026.